337 related articles for article (PubMed ID: 30226780)
1. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.
Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R
Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line.
Rao M; Murali S; Amores D; Yu F; Tsourkas A
Bioconjug Chem; 2024 Jan; 35(1):115-124. PubMed ID: 38173338
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
5. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging.
Ren S; Sun X; Wang H; Nguyen TH; Sadeghipour N; Xu X; Kang CS; Liu Y; Xu H; Wu N; Chen Y; Tichauer K; Minh DDL; Chong HS
ChemMedChem; 2018 Dec; 13(24):2606-2617. PubMed ID: 30403833
[TBL] [Abstract][Full Text] [Related]
7. Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.
Sato K; Watanabe R; Hanaoka H; Harada T; Nakajima T; Kim I; Paik CH; Choyke PL; Kobayashi H
Mol Oncol; 2014 May; 8(3):620-32. PubMed ID: 24508062
[TBL] [Abstract][Full Text] [Related]
8. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
10. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
11. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
13. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
14. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
Greene MK; Chen T; Robinson E; Straubinger NL; Minx C; Chan DKW; Wang J; Burrows JF; Van Schaeybroeck S; Baker JR; Caddick S; Longley DB; Mager DE; Straubinger RM; Chudasama V; Scott CJ
Br J Cancer; 2020 Nov; 123(10):1502-1512. PubMed ID: 32913288
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
18. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
19. Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.
Okada R; Kato T; Furusawa A; Inagaki F; Wakiyama H; Fujimura D; Okuyama S; Furumoto H; Fukushima H; Choyke PL; Kobayashi H
Cancer Immunol Immunother; 2022 Aug; 71(8):1877-1887. PubMed ID: 35013765
[TBL] [Abstract][Full Text] [Related]
20. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab.
Kim N; Cho D; Kim H; Kim S; Cha YJ; Greulich H; Bass A; Cho HS; Cho J
Int J Cancer; 2020 Apr; 146(8):2194-2200. PubMed ID: 31290142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]